GSK plc
HealthcareNYSE:GSK · New York Stock Exchange
+$0.18 today
Vol 3.81M · Avg 4.07M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
35.0%
avg -146.0%
ROIC
16.6%
avg 10.1%
ROA
9.4%
avg 7.7%
Analysis
ROE is currently the strongest return metric at 35.0% versus its period average of -146.0%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Emma Natasha Walmsley | Executive Officer | $7.54M | — | 57 | — | — |
Luke V. Miels | Chief Executive Officer & Director | $6.07M | — | 52 | — | — |
Julie Brown | Chief Financial Officer & Executive Director | $6.01M | — | 64 | — | — |
Jesse L. Goodman | Scientific & Medical Expert | $83,000.00 | — | 75 | — | — |
Constantin Fest | Senior Vice President & Head of Investor Relations | — | — | 49 | — | — |
Shobie Ramakrishnan | Chief Digital & Technology Officer | — | — | 55 | — | — |
David Simon Redfern | President of Corporate Development | — | — | 60 | — | — |
James Ford | Senior Vice President & Group General Counsel of Legal & Compliance | — | — | — | — | — |
Philip C. Thomson | President of Global Affairs | — | — | — | — | — |
Tony Wood | Chief Scientific Officer and Head of R&D | — | — | — | — | — |
Diana Conrad | Chief People Officer | — | — | — | — | — |
Roanne Parry | Chief People Officer | — | — | 52 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +23.9% | +2.2% (15yr)3 analysts |
| Revenue | N/A | N/A | -3.3% | +5.1% (15yr)8 analysts |
| Net Income | N/A | N/A | +23.2% | -2.1% (15yr)8 analysts |
| EBIT | N/A | N/A | +12.2% | +2.0% (15yr)8 analysts |
Analysis
Recent growth has been strongest in EPS at +23.9% over three years. Forward estimates point to Revenue at +5.1% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
CVS Health Corporation
NYSE:CVS
$130.09B
Bristol-Myers Squibb Company
NYSE:BMY
$116.66B
Vertex Pharmaceuticals Incorporated
NASDAQ:VRTX
$112.92B
Sanofi
NASDAQ:SNY
$106.39B
McKesson Corporation
NYSE:MCK
$94.25B
Elevance Health Inc.
NYSE:ELV
$87.75B
HCA Healthcare, Inc.
NYSE:HCA
$85.89B
Cigna Corporation
NYSE:CI
$78.83B
Zoetis Inc.
NYSE:ZTS
$33.36B
Bristol-Myers Squibb Company Ce
CELG-RI
$250.97M
Who manages GSK?
GSK plc (GSK) lists 12 active executives. The top listed executive is Constantin Fest, Senior Vice President & Head of Investor Relations.
Explore More
Continue the stock analysis
Jump to another research area for this company.